Thank you, Mr. Chair.
Thank you to all the witnesses.
I'll be quick because I only have four minutes for my comments.
What our witnesses are saying is very interesting. Based on what I'm hearing from them, I wonder if we shouldn't approach the issue from a completely different angle when it comes to administration and research—but perhaps I'm naive to think so.
Large countries, such as the United States, India and China, are doing research just like us. Do they actually communicate all the information they collect? It seems that they do, in some cases. So what is the added value for Canada?
Canada is often told that it is a small country with a small market and has no power or influence. What is the benefit to Canada of spending millions of dollars to maintain its administrative structures for drug management and research approval and to continue to want to become a leader in the research community?
Following on from what Dr. Yusuf was saying, it may be better to take advantage of what is already being done elsewhere in research and production, what is already approved by such industrialized countries as ours, which has a comparable geography and standard of living to these countries. We could then invest more in education and behaviour change, and prevent companies from giving Canadians bad habits.
I'll stop there. I took one minute and fifteen seconds of my time, which gives you three minutes to respond, Mr. Edwards or Dr. Yusuf.